East Brunswick, NJ, United States

Savient Pharmaceuticals

www.savientpharma.com
East Brunswick, NJ, United States

Savient Pharmaceuticals was a New Jersey based biopharmaceutical company. Its lead product, Krystexxa, known generically as pegloticase, is a biologic drug for treatment resistant chronic gout, which it has marketed since 2011. It has also marketed Oxandrin since 1995.Savient, incorporated in 1980, is focused on commercializing Krystexxa in the United States and completing the development and seeking regulatory approval in the European Union. The company also sells branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. Savient does not own or operate its own manufacturing facilities and uses third-party contract manufacturers under the supervision of company personnel. Its CEO from February 2011 until February 2012 was John H. Johnson, who like most of his executive staff, formerly worked at Imclone Systems.In November 2011, Savient and Jim Belushi collaborated on an educational campaign to raise awareness about refractory chronic gout , for which Krystexxa is being marketed.On August 14, 2013, Savient said in the Q2 10Q filing: "we believe that our available cash, cash equivalents and short-term investments, which includes the net proceeds of the transactions discussed above, will be sufficient to fund anticipated levels of operations for at least the next twelve months from the date hereof."But in October 2013, only two months later, Savient filed for Ch 11 bankruptcy. The Friday before the Monday announcement, the three Co-Presidents were each granted $200K USD bonuses to remain through the sale.In December 2013, Savient was sold to Crealta for approximately $120M USD. Creditors took some loss, and existing shareholders took a near total loss. Wikipedia.


Time filter

Source Type

Patent
Savient Pharmaceuticals | Date: 2013-08-21

Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.


Patent
Savient Pharmaceuticals | Date: 2012-05-01

Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.


Patent
Savient Pharmaceuticals | Date: 2010-09-10

The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.


Patent
Savient Pharmaceuticals | Date: 2011-09-07

The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.


Patent
Savient Pharmaceuticals | Date: 2011-05-13

The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.


Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.


Patent
Savient Pharmaceuticals | Date: 2012-09-20

The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.


Patent
Corelab Partners Inc. and Savient Pharmaceuticals | Date: 2010-06-25

Systems and methods for assessment of the reduction of tophus burden with effective urate-lowering therapy were developed. The first application of computer-assisted methods for accessing tophus response included standardized digital photography, computer assisted measurement and analysis of tophi by an independent reader and blinded central reader paradigm. The ability of the method for computer-assisted analysis of digital photographs to quantify reduction in tophus size demonstrates its feasibility as a urate-lowering therapy monitoring tool in the treatment of tophaceous gout.


Patent
Savient Pharmaceuticals | Date: 2012-04-20

The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.


Loading Savient Pharmaceuticals collaborators
Loading Savient Pharmaceuticals collaborators